Galapagos delivers validated oncology targets to Janssen

26-Apr-2011 - Belgium

Galapagos NV announced that its BioFocus service division has delivered a panel of validated oncology targets in its collaboration with Janssen Research & Development, a division of Janssen Pharmaceutica N.V. (Janssen).  Per the agreement, Janssen retains full rights to discover, develop and commercialize novel medicines on these targets.

In January 2008, BioFocus entered into a fee-for-service target discovery collaboration with Janssen, under which BioFocus developed assays in cancer cells, and discovered and validated novel targets.  In January 2010, BioFocus received a target acceptance payment from Janssen for identifying and validating drug targets.  BioFocus has now confirmed the activity of a panel of targets across several key pathways in oncology, per contractually defined criteria.  BioFocus may receive success-based payments should certain downstream criteria be reached by Janssen.

"We continue to see strong demand for our target discovery capabilities and this collaboration is an example of how we deliver novelty to pharmaceutical pipelines," said Onno van de Stolpe, Chief Executive Officer of Galapagos. 

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances